(EYPT) EyePoint Pharmaceuticals, Inc. Business Model Canvas Research

Ocumension Therapeutics gives EyePoint Pharmaceuticals, Inc. a local route into China and wider Asia, where ophthalmology launches depend on local access, reimbursement, and field execution. In a market with 1.4 billion people, regional partners matter because they can speed commercialization and support international development.

• China and Asia market access
• Local reimbursement know-how
• Faster launch execution
• Supports global expansion

In FY2025, EyePoint Pharmaceuticals, Inc. leaned on 2 outside partnerships, with Equinox Science, LLC and OncoSil Medical UK Limited, to add development and business-development capacity beyond its core U.S. commercialization base. These ties help push pipeline progress and widen market access, while also showing EyePoint still depends on external partners to extend reach and execution.

• 2 partners extend pipeline support
• Outside U.S. commercialization capacity
• Broader reach, less in-house burden

EyePoint Pharmaceuticals, Inc. runs strategic alliance management as a core recurring task because its business relies on external partners for regional commercialization, co-promotion, and development support across its 2 marketed products, DEXTENZA and YUTIQ. In 2025/2026, keeping partner terms, milestones, and territory rights aligned helps protect revenue flow and lower execution risk.

• Manages multiple external partnerships
• Supports regional commercialization
• Enables co-promotion and development support
• Requires ongoing oversight and renewal work

EyePoint Pharmaceuticals, Inc. relies on close medical affairs work with retina and ophthalmology specialists because adoption of sustained-release eye therapy depends on clear clinical proof and practical dosing guidance. Medical-scientific communication also helps explain value to prescribers and payers, which matters when the company is spending heavily on R&D and market education.

• Retina and ophthalmology KOL engagement
• Education on sustained-release delivery
• Scientific support for payer adoption

EyePoint Pharmaceuticals, Inc. depends on clinical, regulatory, and commercial expertise to move ophthalmology assets from trial design to FDA meetings to launch. This matters in a niche eye-care market where specialty drugs need precise evidence, clear labeling, and tight payer access, so the team’s skill set is a core resource.

• Designs ophthalmology trials
• Manages FDA interactions
• Supports specialty drug launch
• Drives market access in niche care

EyePoint Pharmaceuticals, Inc. uses a partner network and operations in the United States, China, and the United Kingdom to extend execution speed and market access. This reach is an intangible asset because it supports local delivery, regulatory follow-through, and deal flow without building every function in-house.

• U.S., China, U.K. footprint
• Local partner execution capacity
• Intangible network advantage

YUTIQ targets chronic non-infectious uveitis affecting the posterior segment, a condition that drives about 10%-15% of U.S. blindness cases. Its 0.18 mg fluocinolone acetonide implant is designed to release medicine for up to 36 months, helping give long-duration control where repeated steroid treatment still leaves a clear unmet need.

• Posterior-segment uveitis focus
• Up to 36 months of drug release
• Built for chronic disease control
• Addresses unmet need in vision loss

EyePoint Pharmaceuticals, Inc. stays tightly focused on ophthalmology, especially retinal disease, so its products and evidence base speak directly to eye specialists. That narrow scope builds physician familiarity and a clear clinical identity, which matters in a U.S. eye-care market with about 19,000 ophthalmologists and 18,000 optometrists.

• Targets a narrow eye-disease niche.

• Matches specialist workflows closely.

• Supports clearer clinical positioning.

EyePoint Pharmaceuticals, Inc. likely builds access and reimbursement support into its customer relationships because ophthalmic drugs often need payer checks, prior authorization, and coverage coordination before treatment starts. That support can speed adoption in real-world care, especially for specialty retina products where delayed approval can slow starts.

• Helps with payer and coverage steps
• Supports prior authorization
• Can speed real-world uptake

EyePoint Pharmaceuticals, Inc. builds longer customer ties because its products are used in chronic, repeat-care settings, not one-time cures. YUTIQ delivers fluocinolone acetonide over 36 months, so retention hinges on real-world outcomes, physician confidence, and strong support for retina specialists and patients.

• 36-month drug delivery supports follow-up care
• Outcome data drives repeat prescribing
• Support services help keep physicians loyal

EyePoint Pharmaceuticals, Inc. uses specialty pharma distribution because ophthalmology products like YUTIQ, a 0.18 mg intravitreal implant, move through specialty channels and provider purchasing systems. That setup helps control access to procedural and implantable therapies and fits reimbursement rules for office-based and hospital settings.

• Controlled access for implant therapies
• Fits provider purchasing workflows
• Supports reimbursement compliance

Scientific conferences and field education matter in specialty pharma because prescriber trust often starts with peer data and live discussion. For EyePoint Pharmaceuticals, Inc., congress presence can lift awareness of DEXTENZA and the pipeline, while field medical teams can turn complex trial readouts into clear clinical use cases.

Recent investor materials show EyePoint is still in a launch-and-pipeline build phase, so these channels help convert scientific visibility into adoption.

• Builds prescriber awareness
• Explains clinical data fast
• Shows pipeline credibility

EyePoint Pharmaceuticals, Inc. serves patients with chronic retinal and inflammatory eye disease, especially diabetic macular edema and chronic non-infectious uveitis. These are long-term conditions, and reducing injection burden matters: the U.S. has about 38.4 million people with diabetes, while non-infectious uveitis is a leading cause of preventable vision loss in working-age adults.

• Long-term disease management
• Fewer clinic visits needed
• Convenience drives adherence

EyePoint Pharmaceuticals, Inc. targets international ophthalmology markets through China and the United Kingdom, where local partners help with commercialization and market access. This matters because the WHO estimates 2.2 billion people live with vision impairment worldwide, so non-U.S. reach can widen demand beyond the domestic base.

• China and UK show non-U.S. activity
• Partners support local sales
• 2.2 billion global vision cases

EyePoint must keep funding multi-phase trials, FDA filings, and post-marketing safety work, and ophthalmic drugs face one of the toughest review paths in pharma. A standard NDA review can take about 10 months, so compliance spend is not optional; it is a permanent cost of selling eye treatments.

• Fund trials from Phase 1 to Phase 3
• Pay for FDA filings and review
• Track post-marketing safety after launch
• Ophthalmology rules stay strict

Partnership and promotion expenses cover shared co-promo, contract setup, and systems integration costs, plus support for market access partners. For EyePoint Pharmaceuticals, Inc., this matters most for DEXYCU and international alliances, where partner support can scale faster than product revenue.

• Co-promo costs are shared.
• Support market access partners.
• DEXYCU and alliances drive spend.

EyePoint Pharmaceuticals, Inc. can earn non-product revenue from licensing, partnerships, and development milestones, a common biotech model that brings upfront cash plus later payments. This structure helps diversify income beyond product sales and can support R&D funding while collaborations advance.

• Upfront license cash
• Milestone-linked payments
• Royalty potential
• Alliance-led value creation

EYP-1901 and YUTIQ50 are EyePoint Pharmaceuticals, Inc.'s main future sales drivers if late-stage development and approval succeed. Both target large ophthalmology markets, with wet AMD alone seeing about 17 million anti-VEGF injections a year in the U.S.; that scale is what makes pipeline commercialization the key upside revenue stream.

• EYP-1901: wet AMD market
• YUTIQ50: uveitis market
• Approval needed for sales